Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment (PIRAT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02523768 |
|
Recruitment Status :
Terminated
(Difficulties for recruting patients)
First Posted : August 14, 2015
Last Update Posted : January 20, 2021
|
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | January 24, 2020 |
| Actual Study Completion Date : | February 24, 2020 |